Related Experiment Video

Updated: Jul 20, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

[Troglitazone sensitizes effect of epirubicin on breast cancer cells]

Jing-Xia Sun1, Zhuo-Xian Meng, Jing-Huan Lv

  • 1Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing 210029, P. R. China.

AI Zheng = Aizheng = Chinese Journal of Cancer
|September 13, 2006
PubMed
Abstract

Insights

Troglitazone enhances epirubicin's effectiveness against ER-negative breast cancer by increasing cell death and reducing migration. This combination therapy shows promise for improving breast cancer treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in breast cancer.
  • Thiazolidinediones (TZD) are PPARgamma ligands that inhibit cancer cell proliferation and induce apoptosis.

Purpose of the Study:

  • Investigate troglitazone (a TZD) as a sensitizer for epirubicin in estrogen receptor (ER) negative breast cancer treatment.
  • Evaluate the combined effects of troglitazone and epirubicin on cancer cell behavior.

Main Methods:

  • Utilized MTT assays and flow cytometry to assess cell proliferation and apoptosis in ER-negative breast cancer cell lines (MDA-MB-435S, MDA-MB-231).
  • Analyzed Bcl-2 expression via Western blot and cell migration using wound healing assays.
  • Compared treatments with troglitazone or epirubicin alone versus co-treatment.

Main Results:

  • Troglitazone significantly enhanced epirubicin's inhibition of breast cancer cell proliferation, reducing epirubicin's IC(50) by 60% at 4-24 micromol/L.
  • Co-treatment with troglitazone and epirubicin induced significant apoptosis (5.48% and 10.08% in MDA-MB-435S and MDA-MB-231 cells, respectively).
  • Combined treatment downregulated Bcl-2 expression and simultaneously inhibited cancer cell migration.

Conclusions:

  • Troglitazone augments epirubicin's efficacy by enhancing proliferation inhibition and apoptosis induction in breast cancer cells.
  • Troglitazone also suppresses breast cancer cell migration, suggesting a multifaceted role in treatment sensitization.
  • Troglitazone shows potential as a sensitizing agent for epirubicin in breast cancer therapy.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...